Pacer Advisors’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.14M Sell
34,025
-948,754
-97% -$66.1M 0.01% 899
2025
Q4
$65.2M Buy
982,779
+922,650
+1,534% +$59.6M 0.17% 135
2025
Q3
$4.05M Sell
60,129
-1,994
-3% -$158K 0.01% 771
2025
Q2
$5.42M Buy
62,123
+22,736
+58% +$1.78M 0.01% 657
2025
Q1
$2.69M Sell
39,387
-11,767
-23% -$960K 0.01% 855
2024
Q4
$3.98M Sell
51,154
-2,378
-4% -$176K 0.01% 707
2024
Q3
$3.59M Buy
53,532
+4,213
+9% +$346K 0.01% 751
2024
Q2
$5.59M Buy
49,319
+4,831
+11% +$611K 0.01% 559
2024
Q1
$6.17M Sell
44,488
-10,686
-19% -$1.34M 0.01% 534
2023
Q4
$6.85M Buy
55,174
+4,056
+8% +$414K 0.02% 497
2023
Q3
$4.77M Sell
51,118
-40,258
-44% -$4.54M 0.02% 477
2023
Q2
$11.7M Sell
91,376
-42,275
-32% -$5.11M 0.05% 339
2023
Q1
$15.5M Buy
133,651
+121,179
+972% +$13.6M 0.07% 288
2022
Q4
$1.41M Sell
12,472
-126,637
-91% -$13.9M 0.01% 674
2022
Q3
$11.2M Buy
139,109
+119,636
+614% +$10.1M 0.08% 206
2022
Q2
$1.45M Sell
19,473
-56,311
-74% -$5.14M 0.01% 479
2022
Q1
$9.69M Buy
75,784
+34,004
+81% +$3.72M 0.08% 250
2021
Q4
$5.61M Buy
41,780
+4,584
+12% +$659K 0.06% 299
2021
Q3
$5.08M Sell
37,196
-1,056
-3% -$133K 0.06% 375
2021
Q2
$4.08M Buy
38,252
+4,488
+13% +$431K 0.06% 413
2021
Q1
$3.03M Sell
33,764
-1,800
-5% -$169K 0.05% 401
2020
Q4
$3.29M Sell
35,564
-21,932
-38% -$1.96M 0.06% 309
2020
Q3
$5.92M Sell
57,496
-3,844
-6% -$402K 0.13% 129
2020
Q2
$6.22M Buy
+61,340
New +$5.49M 0.13% 127
2017
Q4
Sell
-49,588
Closed -$607K 1208
2017
Q3
$607K Buy
49,588
+6,752
+16% +$119K 0.05% 563
2017
Q2
$783K Buy
42,836
+4,340
+11% +$80.2K 0.08% 356
2017
Q1
$815K Buy
38,496
+6,036
+19% +$118K 0.1% 252
2016
Q4
$485K Sell
32,460
-2,020
-6% -$35.8K 0.07% 419
2016
Q3
$756K Buy
34,480
+1,400
+4% +$31.2K 0.11% 179
2016
Q2
$656K Buy
33,080
+27,672
+512% +$471K 0.1% 216
2016
Q1
$92K Sell
5,408
-36
-0.7% -$601 0.02% 636
2015
Q4
$111K Buy
+5,444
New +$113K 0.03% 552

Other funds holding DXCM

Pacer Advisors's DXCM Position: Q1 2026 in Review

Pacer Advisors reduced its DexCom (DXCM) stake by 97% in Q1 2026, selling an estimated $66.1M and leaving 34,025 shares worth $2.14M. The position accounts for 0.01% of the portfolio, ranked #899.

Pacer Advisors first reported a position in DXCM in Q4 2015 and has held it in 32 quarters since. The position peaked at $65.2M in Q4 2025. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Pacer Advisors held 34,025 shares of DexCom worth $2.14M as of Q1 2026.
  • Pacer Advisors sold 948,754 DexCom shares in Q1 2026, an estimated $66.1M.
  • DexCom made up 0.01% of Pacer Advisors's portfolio in Q1 2026, its #899 holding.
  • Pacer Advisors first reported a position in DexCom in Q4 2015 and has held it in 32 quarters since.
  • Pacer Advisors's DexCom position peaked at $65.2M in Q4 2025.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.